Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536

Published:2010-02-09 Issue:4 Volume:70 Page:1513-1523
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Research

Author:

Gleixner K. V.,Ferenc V.,Peter B.,Gruze A.,Meyer R. A.,Hadzijusufovic E.,Cerny-Reiterer S.,Mayerhofer M.,Pickl W. F.,Sillaber C.,Valent P.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells;Oncology Letters;2024-05-14

2. The Juxtaposition of Allosteric and Catalytic Inhibition in PLK1: Tradeoff for Chemotherapy and Thermodynamic Profiles of KBJK557 and BI 6727;Journal of Computational Biophysics and Chemistry;2024-01-25

3. A novel L-shaped ortho-quinone analog as PLK1 inhibitor blocks prostate cancer cells in G2 phase;Biochemical Pharmacology;2024-01

4. Polo-like kinase 1 Decrease During Induction Therapy Could Indicate Good Treatment Response, Favorable Risk Stratification, and Prolonged Survival in Pediatric Acute Lymphoblastic Leukemia: [RETRACTED];Journal of Pediatric Hematology/Oncology;2023-02-20

5. Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies;Current Hematologic Malignancy Reports;2022-10-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP